We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · October 06, 2022

Effect of Inhaled Treprostinil Dose in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease



Additional Info

Disclosure statements are available on the authors' profiles:

Inhaled Treprostinil Dose in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Outcomes
Chest 2022 Sep 14;[EPub Ahead of Print], SD Nathan, C Deng, CS King, HM DuBrock, J Elwing, S Rajagopal, F Rischard, S Sahay, M Broderick, E Shen, P Smith, VF Tapson, AB Waxman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading